摘要
嘌呤能系统由嘌呤和嘧啶递质、调节核苷酸和核苷相互转化的酶、控制它们的受体的膜转运体组成。无细胞浓度,以及许多受体亚型,负责他们的细胞反应。这个系统的组成部分在所有的组织和器官中都有广泛的定位。R参与了几种生理条件已被清楚地证明。此外,在像tiss这样的病理条件下,细胞外嘌呤和嘧啶的浓度增加了几倍。UE损伤,缺血和炎症,这表明这一信号系统可能有助于疾病的结果,并可能,它的初步解决。这个系统的复杂性由于不同的受体亚型所扮演的角色往往相反,实际上参与某一特定病理过程的介质和受体的明确识别受到了严重的损害。n然而,这些知识对于可能利用这些分子实体作为开发新的药理方法的目标是非常重要的。在这篇综述中,我们的目标是高效率。了解目前已知的嘌呤能系统在各种疼痛状态和炎症过程中的作用。虽然有些混淆可能会从相互矛盾的结果中产生,但文献数据清楚地表明,靶向特定的嘌呤能受体可能是治疗各种疼痛和炎症状态的一种创新方法,而新的嘌呤类药物现在非常接近r。每个市场都有这些迹象。
关键词: P1受体、P2X受体、P2Y受体、腺苷、ATP、UTP、核糖核苷酶、膜转运蛋白。
Current Medicinal Chemistry
Title:Tackling Chronic Pain and Inflammation through the Purinergic System
Volume: 25 Issue: 32
关键词: P1受体、P2X受体、P2Y受体、腺苷、ATP、UTP、核糖核苷酶、膜转运蛋白。
摘要: The purinergic system is composed of purine and pyrimidine transmitters, the enzymes that modulate the interconversion of nucleotides and nucleosides, the membrane transporters that control their extracellular concentrations, and the many receptor subtypes that are responsible for their cellular responses. The components of this system are ubiquitously localized in all tissues and organs, and their involvement in several physiological conditions has been clearly demonstrated. Moreover, extracellular purine and pyrimidine concentrations rise several folds under pathological conditions like tissue damage, ischemia, and inflammation, which suggest that this signaling system might contribute both to disease outcome and, possibly, to its tentative resolution. The complexity of this system has greatly impaired the clear identification of the mediators and receptors that are actually involved in a given pathology, also due to the often opposite roles played by the various receptor subtypes. Nevertheless, this knowledge is fundamental for the possible exploitation of these molecular entities as targets for the development of new pharmacological approaches. In this review, we aim at highlighting what is currently known on the role of the purinergic system in various pain conditions and during inflammatory processes. Although some confusion may arise from conflicting results, literature data clearly show that targeting specific purinergic receptors may represent an innovative approach to various pain and inflammatory conditions, and that new purine-based drugs are now very close to reach the market with these indications.
Export Options
About this article
Cite this article as:
Tackling Chronic Pain and Inflammation through the Purinergic System, Current Medicinal Chemistry 2018; 25 (32) . https://dx.doi.org/10.2174/0929867324666170710110630
DOI https://dx.doi.org/10.2174/0929867324666170710110630 |
Print ISSN 0929-8673 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-533X |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Glutamate and Multiple Sclerosis
Current Medicinal Chemistry The Endocannabinoid System in Peripheral Lymphocytes as a Mirror of Neuroinflammatory Diseases
Current Pharmaceutical Design Oxidative Stress, Pro-Inflammatory Cytokines, and Antioxidants Regulate Expression Levels of MicroRNAs in Parkinson’s Disease
Current Aging Science Life and Death of Nerve Cells: Therapeutic Cytokine Signaling Pathways
Current Signal Transduction Therapy Targeting Vascular Changes in Lesions in Multiple Sclerosis and Experimental Autoimmune Encephalomyelitis
Central Nervous System Agents in Medicinal Chemistry Simulating the Interactions of Toxins with K+ Channels
Current Pharmaceutical Design Regulatory T Cells and Tolerogenic Dendritic Cells as Critical Immune Modulators in Atherogenesis
Current Pharmaceutical Design Type 2 Diabetes Mellitus and Alzheimer’s Disease: Bridging the Pathophysiology and Management
Current Pharmaceutical Design Engineering Biomimetic Materials for Islet Transplantation
Current Diabetes Reviews Immunomodulation of the Allergic Inflammatory Response: New Developments
Inflammation & Allergy - Drug Targets (Discontinued) Fibrinogen Signal Transduction as a Mediator and Therapeutic Target in Inflammation:Lessons from Multiple Sclerosis
Current Medicinal Chemistry Role of Lipopolysaccharides in Potential Applications of Nanocarrier Systems
Current Pharmaceutical Design Preparation of Knockout Extract for Determination of Really Active Compound Using MAb
Current Drug Discovery Technologies Molecular Imaging of Stem Cell Transplantation for Neurodegenerative Diseases
Current Pharmaceutical Design (Neuro)Transmitter Systems in Circulating Immune Cells: A Target of Immunopharmacological Interventions?
Current Medicinal Chemistry The Role of HTS in Drug Discovery at the University of Michigan
Combinatorial Chemistry & High Throughput Screening Editorial [Hot Topic: New Drugs and Drug Targets for Human Diseases Caused by Apicomplexan Parasites (Guest Editor: Frank Seeber)]
Current Drug Targets Micro- and Nano-particulate Strategies for Antigen Specific Immune Tolerance to Treat Autoimmune Diseases
Pharmaceutical Nanotechnology IL-17A and Multiple Sclerosis: Signaling Pathways, Producing Cells and Target Cells in the Central Nervous System
Current Drug Targets Other Future Targeting Therapy Beyond TNF-α Inhibitor in Patients with Spondyloarthropathy
Current Rheumatology Reviews